SÉZARY SYNDROME
Clinical trials for SÉZARY SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SÉZARY SYNDROME trials appear
Sign up with your email to follow new studies for SÉZARY SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug INCA036873 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…
Matched conditions: SÉZARY SYNDROME
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to control Hard-to-Treat skin lymphoma
Disease control Recruiting nowThis study tests whether combining two drugs, pembrolizumab and mogamulizumab, can shrink or control advanced cutaneous T-cell lymphoma (a type of skin cancer) that has returned or not responded to prior therapy. About 23 adults with stage IIB to IVB disease will receive the drug…
Matched conditions: SÉZARY SYNDROME
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for rare skin cancer: experimental drug enters human trial
Disease control Recruiting nowThis early-phase trial tests an investigational drug called ropeginterferon in 38 adults with cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants must have tried at least two prior treatments without success. The main goals are to find the safest dose and s…
Matched conditions: SÉZARY SYNDROME
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for Tough-to-Treat T-Cell lymphoma? pacritinib trial opens
Disease control Recruiting nowThis study tests a drug called pacritinib in 100 people with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug and are monitored with scans and skin asse…
Matched conditions: SÉZARY SYNDROME
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill takes on tough lymphoma: early trial seeks tumor shrinkage
Disease control Recruiting nowThis early-phase trial tests an oral drug called TLN-254 in about 50 adults with relapsed or refractory T-cell lymphoma. The main goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug by mouth on a set schedule, and researchers will monitor r…
Matched conditions: SÉZARY SYNDROME
Phase: PHASE1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Global study aims to predict outcomes for rare skin lymphoma patients
Knowledge-focused Recruiting nowThis study is collecting medical information from 2000 people with advanced mycosis fungoides or Sézary syndrome, two rare types of skin lymphoma. The goal is to create a tool that helps doctors predict which patients are at higher or lower risk, so they can tailor treatments mor…
Matched conditions: SÉZARY SYNDROME
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC